Furthermore, the synergy in the anti-CD40, CpG, and monophosphoryl lipid A (MPL) treatment was observed to activate TAMs via CD40/TLR9 ligation to kill tumor cells in vitro and inhibit tumor growth in vivo (Buhtoiarov et al. 2006; Shi et al. 2015). The gene discussed is TLR9; the disease is neoplasm.